Anthony Davies looks ahead to the rest of 2021

Happy Eve of Not #JPMorgan: here are my in-no-particular-order Top 10 predictions for the year in cell and gene therapy, not so much as a Nostradamus impression, but hopefully more a provocation of thought… 

#1 The investment and acquisition arms race in the CTx and GTx tools & technology space will continue, with valuations that baffle us all, especially for CMOs
#2 mRNA-nanoparticle technology will become regarded as a bona fide GTx, expand out of its world-changing year in vaccinology, and comprise the first for-real competitor to viral vector technology
#3 Regulators will continue to drop the hammer on CMC, especially, but not limited to, potency assays: sponsors will howl they are suddenly ‘tightening up,’ but cooler heads will remind the CGTx field it’s simply maturing to a point where regulators have always been strict
#4 What’s going on with toxicity and high-dose AAV will be clarifiedand it won’t be good news for high-dose AAV. Capsid engineering could save the day, but only if it actually shows effectiveness of reduced doses
#5 The myth of mesenchymal stem cells being all-seeing, all-knowing, anti-inflammatory, ‘smart cells,’ ‘cells that know what disease needs to be treated and do what needs to be done,’ will finally die: everyone, we wish they did, but they don’t work
#6 Allogeneic CAR-T, NK etc. therapies will either show a definitive CMC advantage (= consistently high doses/donor) or risk being considered insufficiently differentiated from their autologous competitors
#7 For the first time in 20 years, scale-up and consistency of Adenovirus (yes, not the Associated Virus) will become really importantand not just for viral vaccines
#8 CGTx clinical assets will become commodities, in a good way, enabling companies with rich and diverse pipelines to monetize and streamline

#9 Scott Gottlieb, M.D. will return as FDA Commissioner, to a ticket tape parade and rows of CoVID-19-vaccinated staffers prostrating at his feet and the sound of a chorus of angels (just kidding about the angelic choir – umm, kind of – but well done for reading this far)

And #10 (this one’s for 2022): hotel room rates in the second week of January in San Francisco will drop back into the triple digit $. I just hope there’s still a #JPMorgan conference there for us to avail of them…

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.